key: cord-0831255-ofcthc5o
authors: Macfarlane, Gary J; Hollick, Rosemary J; Morton, LaKrista; Heddle, Maureen; Bachmair, Eva-Maria; Anderson, R Stuart; Whibley, Daniel; Keenan, Karen Forrest; Murchie, Peter; Stelfox, Kevin; Beasley, Marcus J; Jones, Gareth T
title: The effect of COVID19 public health restrictions on the health of people with musculoskeletal conditions and symptoms: the CONTAIN study
date: 2021-04-21
journal: Rheumatology (Oxford)
DOI: 10.1093/rheumatology/keab374
sha: 8a67d731a407ed1a302a9dc14babf6e3ab00475f
doc_id: 831255
cord_uid: ofcthc5o

OBJECTIVE: To quantify the change in quality of life, disease-specific indicators, health, and lifestyle before and during the COVID19 pandemic amongst people with musculoskeletal diagnoses and symptoms. METHODS: We undertook an additional follow-up of two existing UK registers involving people with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) and participants in a trial in the UK who had regional pain and were identified at high risk of developing chronic widespread pain. Participants completed the study questionnaire between July and December 2020, throughout which time there were public health restrictions in place. RESULTS: 1054 people took part in the study (596 axSpA, 162 PsA, 296 regional pain). In comparison to their previous (pre-pandemic) assessment, there was an age-adjusted significant, small, decrease in quality of life measured by EQ-5D (-0.020 95% CI (-0.030, -0.009)) overall and across all population groups examined. This was primarily related to poorer mental health and pain. There was a small increase in fibromyalgia symptoms, but a small decrease in sleep problems. There was a small deterioration in axSpA disease activity, and disease-specific quality of life and anxiety in PsA participants. Predictors of poor quality of life were similar pre- and during the pandemic. The effect of lockdown on activity differed according to age, gender, and deprivation. CONCLUSION: Important lessons include focussing on addressing anxiety and providing enhanced support for self-management in the absence of normal health care being available, and awareness that all population groups are likely to be affected.

The COVID-19 pandemic resulted in unprecedented changes to the life of people throughout the world during 2020. Although specific measures varied according to country, generally public health measures were put in place across a very short space of time around March, to reduce the spread of the virus. In the United Kingdom, from 23 rd March 2020 measures were put in place which confined most people to their home and meant they were only able to leave for a limited number of reasons and people identified as "vulnerable" were advised to "shield" in their home. Subsequent to the national lockdown, there was a gradual easing of restrictions beginning in May 2020 but with a rise in the number of cases of infection due to COVID19 at the end of August 2020 there was then a series of local and national (specific to England, Scotland, Wales, and Northern Ireland) public health restrictions put in place which have remained into 2021.

Musculoskeletal health can be supported and maintained by physical activity and getting an adequate duration and quality of sleep. Related to these factors, poor mental health is an important determinant of reduced health-related quality of life (1) and a marker for poor disease outcome in both pain (2, 3) and inflammatory arthritis (4) . Individuals' mental health may have been affected by the amount of time required to be spent at home and the resulting social isolation, as well as anxiety around the pandemic and concerns about health. Most people in work will have experienced important changes: some working in stressful circumstances, others making the transition to home working while some may either have been furloughed or lost their job. An interim report of a survey by the Institute of Employment Studies, involving five hundred people working at home, reported a significant increase in musculoskeletal complaints (5) . More than half of respondents said they were exercising less, while around two thirds reported loss of sleep due to worry.

While many research studies chose to undertake ad hoc surveys of convenience samples of people, we undertook additional follow-ups of well-characterised groups with musculoskeletal conditions and symptoms. Future reports from the study will consider impact on health service usage and experience of healthcare received, and impact on work. This analysis is focussed on the health of respondents during the public health restrictions associated with the pandemic and specifically how this had changed since they were previously surveyed.

The CONTAIN study (COvid-19 aNd musculoskeleTal heAlth durIng lockdown) re-surveyed three cohorts of patients with musculoskeletal disease or symptoms using a questionnaire comprising existing validated instruments and questions specific to their experience during the COVID19 pandemic. The cohorts were patients with axial spondyloarthritis (BSRBR-AS) (6) , psoriatic arthritis (BSR-PsA) (Protocol: https://osf.io/jzs8n) and patients with regional musculoskeletal pain who were at risk of chronic widespread pain and enrolled in the MAmMOTH randomised controlled trial (7) .

Further details of the study cohorts are given in the Supplementary Text.

All potential participants received a letter by post (or an email if details were available) over the period June-July 2020. Those who received an email but did not respond were then sent a letter by post. The communication explained about the study and invited recipients to go online to access the patient information sheet, consent to participate and to complete the study questionnaire, which was specific to their cohort. For those people who wished to participate but were unable to complete the questionnaire online, we provided email and telephone contact details to request a mailed questionnaire. When we were able to do so (from mid-July 2020) these were sent out. Reminder letters were sent by post from September 2020.

The questionnaire asked about demographic and employment information, and deprivation was computed with reference to either the population of Scotland (8) or England (9) & Wales (10), and, along with the classification of residence as urban or rural, was determined by participants' postcodes. Common across all three cohorts, the questionnaire collected health information including Quality of Life (EQ-5D-5L) (11), sleep problems (12), quantitative measurement of fibromyalgia symptoms through the fibromyalgia severity (FS) score from the 2011 research criteria (13) and questions in relation to COVID19. There were also specific questionnaires for individual cohorts: 

To examine the change in measures from the last survey timepoint, mixed effects regression models were used, with individual participant as a random effect. Only participants who had the measure available at each timepoint were included in these analyses. For EQ5D-5L, the Jenkins Sleep Problem Scale, fibromyalgia severity, ASQoL, BASDAI, BASFI, PROMIS Anxiety, PROMIS Depression, and PSAQOL, mixed effects linear regression was used. For changes in the individual items of the EQ5D-5L, and in IPAQ category, mixed effects ordinal logistic regression, and mixed effects multinomial logistic regression were used respectively. Analyses were first carried out for the whole sample, then stratified by demographic characteristics and clinical characteristics. Analyses were adjusted for age at time of data collection, and appropriate effect sizes reported with 95% confidence intervals: mean difference for linear regression; odds ratios (ORs) for logistic and ordinal logistic regression, and multinomial odds ratios (MORs) for multinomial logistic regression. In order to examine for the effects of non-participation by age, gender, deprivation, and study cohort, a weighted analysis was run with weights determined by the inverse of the probability of persons in these population sub-groups participating in the CONTAIN study.

To examine predictors of EQ5D-5L, two linear regression models were run, one for pre-pandemic predictors of pre-pandemic EQ5D-5L and the other pre-pandemic predictors of current EQ5D-5L.

Regression coefficients with 95% confidence intervals were reported. To provide an estimate of the size of the difference in association between these time points, a mixed effects linear regression was carried out for each predictor with an interaction between the predictor and the timepoint (previous timepoint or current survey). The interaction term is reported with 95% confidence intervals.

The analysis uses the 14 th December 2020 version of the database; all analyses were conducted using STATA SE 15.1.

A total of 1054 persons who filled in a study questionnaire were included in the analysis (596 from BSRBR-AS, 162 from BSR-PsA, and 296 from MAmMOTH), representing 29% of those invited (27% from BSRBR-AS; 26% from BSR-PsA; 33% from MAmMOTH). Amongst the respondents 43% completed the questionnaire in July 2020, 25% in August-September, and 32% in October-December. The median time since last follow-up was 1002 days for BSRBR-AS participants, 249.5 days for BSR-PsA and 635 days for MAmMOTH. Overall, the median age of participants was 59 years (Inter-quartile range (IQR) 47-69 years), 55% were male, while 50% reported that they were in full or part-time work and 34% were retired. Thirty percent of the sample were (based on their postcode) resident in an area classified as rural while the sample over-represented those with low levels of deprivation (58% were in the highest two quintiles of deprivation). Of the 523 respondents who reported that they were in paid employment, 205 identified themselves as a "key worker", while a total of 390 (37%) respondents indicated that they had been advised to shield. Only 1.6% of respondents stated that they had had COVID19 , a further 8.4% reported that they had COVID19-related symptoms and 10.1% were unsure if they had COVID-related symptoms; the vast majority of respondents (75.2%) reported that they had not had COVID19-related symptoms.

In comparison to the previous assessment there was an age-adjusted significant decrease in quality of life (EQ-5D-5L mean difference (md) age-adjusted -0.020 95% CI (-0.030, -0.009)). This was noted across all age-groups, amongst males and females, across all levels of deprivation, time periods of completion and work status, although not all were statistically significant ( Table 1) . Analysis of the individual components of EQ-5D 5L demonstrated different effects across domains. There was no difference in relationship to mobility and self-care but, after age-adjustment, respondents were significantly more likely to report higher levels of pain/discomfort and anxiety/depression in comparison to the previous follow-up (OR age-adj 1.63 95% CI (1.35, 1.96), 1.79 95% CI (1.46,2.18) respectively) ( Table 2 ). Over all respondents there was a worsening of fibromyalgia severity score (md age-adjusted 0.42 95% CI (0.18-0.66)), this worsening was noted in both males and females, amongst those resident in areas of low and high deprivation, with the largest change in the early period of follow-up (Table 3 ). In contrast there was a small but significant reduction in sleep problems over all respondents (md age-adjusted -0.52 95% CI (-0.81, -0.22)). This was noted in both males and females, across all age-groups, deprivation categories, study cohort and time period of completion (Table 4 ).

In the two disease cohorts, we examined additional disease-specific measures:

There were no consistent or important age-adjusted differences in terms of disease-specific quality of life (as measured by ASQoL) (md age-adjusted 0.02 95% CI (-0.28, 0.33)). There was also no consistent changes in population sub-groups although it was noted that there was relative improvement of disease-specific quality of life over the period of the study (Table 5a ). Disease activity increased by a small amount (BASDAI md age-adjusted 0.13 95% CI (-0.03, 0.29)) with the largest increase in those resident in areas with the highest levels of deprivation 0.31 95% CI (-0.09, 0.71) and in those followed-up at the earliest time point 0.23 95% CI (0.01, 0.46), although only the latter was statistically significant (Supplementary Table A ). There were no important changes in function (BASFI) (md age-adjusted -0.05 95% CI (-0.19, 0.09)) overall or in any population sub-group (Supplementary Table B ).

There was a significant worsening of quality of life, as measured by the PsAQoL, with an age-adjusted mean difference of 0.75 95% CI (0.19, 1.30); the worsening was mainly observed in those who were advised to, and followed, shielding guidance and those living in urban settings. (Table 5b ). There were no important or significant changes in depression since the last follow up either overall (PROMIS Depression md age-adjusted 0.7 95% CI (-0.6,1.9)) or in population subgroups (Supplementary Table C ). In contrast there was a significant increase in anxiety overall (PROMIS anxiety md age-adjusted 1.7 95% CI (0.5,2.9)) with the greatest increases in anxiety noted in the oldest age group (over 75 years), those resident in the most affluent areas and in the last follow-up period (Supplementary Table D) . Since their previous assessment, while there was a small increase in the number of participants who had low levels of physical activity/were inactive as assessed by the IPAQ (37% v. 32% OR ageadj v. moderate activity 1.78 95% CI (0.78,4.11)) there was a much larger (and statistically significant) increase in the proportion classified as highly active (31% v. 20% OR ageadj 2.54 95% CI (1.14,5.67)). In comparison to previous assessments, high levels of activity were particularly noted in females (MOR ageadj 3.88 95% CI (1.17,12.85)) and low levels of activity in those resident in areas with the greatest levels of deprivation (MOR ageadj 5.27 95% CI (1.27,21.97)) and in the earliest follow-up period. (Supplementary Table E) .

Taking account of non-participation by age, gender and deprivation had little effect on the estimates of change. Specifically, the deterioration in EQ-5D (-0.021 85% CI (-0.035, -0.008)), increase in fibromyalgia severity 0.38 95% CI (0.11, -0.64), and PROMIS anxiety score (1.57 95% CI (0.20, 2.95)) remained and were of a similar magnitude, as was the reduction in sleep problems -0.57 95% CI (-0.89, -0.25). The worsening of disease activity in patients with axSpA was marginally higher and the deterioration was statistically significant 0.18 95% CI (0.01, 0.36).

Three analyses in relation to poor quality of life are reported in Table 6 : using pre-pandemic data to predict pre-pandemic quality of life; using pre-pandemic and pandemic data to predict pandemic quality of life; an analysis looking at the change of strength of association between a factor and prepandemic and pandemic quality of life. The relationship of factors with poor quality of life is very similar pre-and during the pandemic: sleep problems, living in areas with high levels of deprivation, and low levels of physical activity (which could be examined only in PsA). In the mixed effects model (Model 3 in Table 6 ) which included an interaction term for strength of relationship, the only factor showing a change in relationship, was that being a member of the MAmMOTH cohort (i.e. being at risk of developing chronic widespread pain) was associated with relatively poorer quality of life during the pandemic.

There was a small detrimental effect on quality of life for people with musculoskeletal conditions and symptoms during the period of public health restrictions in the UK due to COVID19. The decrease in quality of life was principally related to mental health and pain; and in the cohort for which more detailed information was available on mental health (participants with PsA) this was specifically related to higher levels of anxiety. Participants with PsA reported a decrease in disease specific quality of life while there was an increase in disease activity in participants with axSpA. Factors influencing poor quality of life, and their importance, was similar pre-, and during the pandemic. In contrast there was small improvements in sleep reported overall, while there were both improvements (in females, and at older ages) and deterioration (those resident in areas of high deprivation) in the amount of exercise reported during the restrictions.

Many studies of ill-health during COVID19 were conducted by means of ad hoc internet-surveys promoted through social media (e.g., 20,21). Although these can provide useful information (22), it is difficult for them to assess the magnitude of effects due to recall and being highly selective in terms of persons participating. Our study had the advantage of prospective collection of information before the COVID19 pandemic and during restrictions. Nevertheless, the time period since last follow-up varied considerably between and within studies. Secondly, the six months over which the study was conducted represented different levels of restrictions and also varied depending on where participants lived. Thus, our data need to be interpreted in the general context of restrictions over this period. Thirdly, our patient and patient organisation partners commented to us at the time of designing the survey that there was a perceived "survey fatigue" amongst patients because of the number of internet surveys which were being conducted during the course of the pandemic -and indeed this proved to be the case as participation was relatively low and caused us to issue an (initially unplanned) reminder. This was an issue experienced by others such as Smith et al (23) who reported a 19% participation rate amongst patients registered in the Norfolk Arthritis Register (NOAR) when approached for a COVID19-related survey. We conducted a weighted analysis to take account of sociodemographic factors and reassuringly they showed similar magnitude of change although with a slightly higher estimate for change in BASDAI amongst participants with axSpA. Finally, while we generally saw less impact of lockdown on health over time it is not possible to disentangle this time period effect from the methodological issue of people who were most severely affected responding earlier. Nevertheless, the interpretation of lessening impact with time is generally supported by longitudinal surveys conducted in the general population, for example on mental health (24). This also emphasises that in interpreting the results from the current study we are not concluding that the changes in health were because of their musculoskeletal condition.

There have been several reports about the effect of COVID19 on health in the UK population. An additional sweep of the UK Household Survey in April 2020 showed increased levels of psychological distress (compared to the previous pre-pandemic survey) particularly affecting younger persons and women (24). Poor mental health is a key factor influencing quality of life amongst people with musculoskeletal conditions (1) and also is an independent predictor of response to therapy (25) and thus the effect of the pandemic on mental health in patients with musculoskeletal symptoms and conditions is of relevance to their management and addressing increasing levels of anxiety is likely to be key to maintaining quality of life. An analysis of more than 12,000 people with inflammatory arthritis in the DANBIO register in Denmark reported that females, people with comorbidities, not working, with lower levels of education, on biological treatment and with lower quality of life were more likely both to be anxious and self-isolate (26). to and during the pandemic, sleep duration was longer during lockdown; only 37% did not reach recommended 7 hours of sleep on weekdays during the pandemic compared to 62% pre-pandemic.

However, there was no difference in sleep quality pre-and during the pandemic (31). Retrospective studies asking people to recall sleep patterns have tended to find people reporting worsening as opposed to improvement of sleep during the pandemic (e.g., 32). Other "benefits" noted in the results include significant (positive) changes in the likelihood of respondents being classified as taking high levels of physical activity compared with previously -particularly for older respondents and females.

However, it is noteworthy that these positive effects were not uniformly seen, indeed respondents living in areas with higher levels of deprivation were significantly more likely to be classed as taking low levels of physical activity compared with the previous follow-up. We could not find any other large-scale study of persons with musculoskeletal conditions which had examined impact on taking physical activity during the pandemic.

In summary, this study provides evidence of only a small average decrease in quality of life reported by people with musculoskeletal symptoms or diagnoses during restrictions caused by the COVID19 pandemic, with the main issues being pain and anxiety. There was also some deterioration noted in average disease specific measures, again of small magnitude, an increase in fibromyalgia-related symptoms but a small reduction in sleep problems. Changes were not restricted to particular population groups. The results taken as a whole are generally reassuring but provide some lessons for future similar situations: focussing on addressing anxiety is important, providing enhanced support for self-management (including in relation to pain) in the absence of normal health services being available, and being aware that all patients regardless of circumstances can be affected.

We are grateful to help from staff at the National Ankylosing Spondylitis Society and specifically to patient partners Lynne Laidlaw (for help with designing questionnaire) and Susan Davis (for commenting on the manuscript). The authors do not report any conflicts of interest. GJM conceived the idea for the study and all authors were involved in the detailed planning. MH, KK, EM-B and MB were responsible for obtaining ethics and research governance approvals. MB undertook the analysis which was independently verified by GTJ. GJM, with input from MB, drafted the manuscript, and all authors contributed important intellectual content via written comments. We thank Linda Dean for comments on the manuscript.

The data within the article which relate to the collection of BSR register data are owned by the BSR -access to these data are subject to application being made to the BSR: Registers 

Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS)

Chronic pain: a review of its epidemiology and associated factors in population-based studies

The influence of preoperative psychological distress on pain and function after total knee arthroplasty: a systematic review and meta-analysis

Predicting Functional Disability: One-Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort

Institute for Employment Studies

The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment

Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised